Fredag 12 Juni | 00:45:09 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-25 08:00 Bokslutskommuniké 2026
2026-11-26 08:00 Kvartalsrapport 2026-Q3
2026-08-27 08:00 Kvartalsrapport 2026-Q2
2026-05-28 - X-dag ordinarie utdelning SANION 0.00 SEK
2026-05-27 - Årsstämma
2026-05-26 - Kvartalsrapport 2026-Q1
2026-02-26 - Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning SANION 0.00 SEK
2025-05-28 - Årsstämma
2025-05-28 - Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-29 - Kvartalsrapport 2024-Q1
2024-05-27 - X-dag ordinarie utdelning SANION 0.00 SEK
2024-05-25 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2024
2023-11-30 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-25 - Årsstämma
2023-05-25 - Kvartalsrapport 2023-Q1
2023-05-24 - X-dag ordinarie utdelning SANION 0.00 SEK
2023-02-23 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-08-18 - Extra Bolagsstämma 2022
2022-05-27 - X-dag ordinarie utdelning SANION 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-09-16 - Extra Bolagsstämma 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning SANION 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-03-17 - Bokslutskommuniké 2020
2020-11-30 - Kvartalsrapport 2020-Q3
2020-10-23 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning SANION 0.00 SEK
2020-05-06 - Årsstämma
2020-05-06 - Kvartalsrapport 2020-Q1
2020-02-07 - Extra Bolagsstämma 2019
2020-02-07 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-31 - X-dag ordinarie utdelning SANION 0.00 SEK
2019-05-29 - Årsstämma
2019-05-29 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning SANION 0.00 SEK
2018-05-24 - Årsstämma
2018-05-24 - Kvartalsrapport 2018-Q1
2018-02-21 - Bokslutskommuniké 2017
2018-01-19 - Extra Bolagsstämma 2018
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-24 - X-dag ordinarie utdelning SANION 0.00 SEK
2017-05-23 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-21 - Bokslutskommuniké 2016
2016-10-13 - Extra Bolagsstämma 2016
2016-05-11 - X-dag ordinarie utdelning SANION 0.00 SEK
2016-05-10 - Årsstämma
2016-05-10 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-20 - Kvartalsrapport 2015-Q3
2015-09-04 - Extra Bolagsstämma 2015
2015-08-31 - Kvartalsrapport 2015-Q2
2015-05-21 - X-dag ordinarie utdelning SANION 0.00 SEK
2015-05-20 - Årsstämma
2015-05-20 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-21 - Kvartalsrapport 2014-Q3
2014-08-22 - Kvartalsrapport 2014-Q2

Beskrivning

LandDanmark
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Saniona är verksamt inom bioteknikbranschen och fokuserar på utveckling av behandlingar för neurologiska och psykiatriska sjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. Saniona grundades 2011 och har sitt huvudkontor i Glostrup, Danmark.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-04 08:00:00

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces that it will host a virtual R&D Day focusing on SAN2668, Saniona's novel treatment candidate for severe pediatric epilepsies, and featuring leading pediatric epilepsy expert Nicola Specchio, MD, PhD.

The webinar will discuss the significant unmet need and current treatment landscape for severe pediatric epilepsies, including developmental and epileptic encephalopathies (DEEs), and review the scientific rationale, preclinical data, and planned clinical development strategy for SAN2668.

The event will take place on Wednesday, June 17, 2026, at 10:00 AM ET (16:00 CET). To register for the event, click here.

"We believe SAN2668 represents an important opportunity to address the significant unmet needs that remain in severe pediatric epilepsies, where many children continue to experience debilitating seizures despite available treatment options," said Thomas Feldthus, Chief Executive Officer of Saniona. "We are delighted to welcome Dr. Nicola Specchio to discuss the disease landscape and current treatment challenges, while also reviewing the scientific rationale and development strategy supporting SAN2668."

The webinar will feature Nicola Specchio, MD, PhD, Head of the Rare and Complex Epilepsies Unit at Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Dr. Specchio is a globally recognized expert in pediatric epilepsy and principal investigator in numerous clinical studies focused on developmental and epileptic encephalopathies and other severe childhood epilepsies.

Joined by members of Saniona's management team, Dr. Specchio will discuss the substantial unmet medical need and current treatment landscape for severe pediatric epilepsies. These disorders are often highly drug resistant, associated with significant seizure burden and developmental impairment, and can have lifelong consequences for patients and their families.

As the first in a planned series of webinars highlighting Saniona's differentiated CNS pipeline, the event will provide an overview of SAN2668, including:

  • The scientific rationale for targeting GABAA receptors in severe pediatric epilepsies
  • Key preclinical data supporting the development of SAN2668
  • The planned Phase 1 clinical development strategy
  • The disease landscape and commercial opportunity in severe pediatric epilepsies

A live question-and-answer session will follow the presentations.

For those unable to attend the live event, a replay will be made available following the webinar.

If you would like to submit a question for the live Q&A session, please send your question to questions@lifesciadvisors.com.